We have detected that you are using Internet Explorer to visit this website. Internet Explorer is now being phased out by Microsoft. As a result, NHS Digital no longer supports any version of Internet Explorer for our web-based products, as it involves considerable extra effort and expense, which cannot be justified from public funds. Some features on this site will not work. You should use a modern browser such as Edge, Chrome, Firefox, or Safari. If you have difficulty installing or accessing a different browser, contact your IT support team.
COVID-19 – high risk shielded patient list identification methodology
Amendments from previous version
Summary
This is a summary of the changes made from Version 1 of the algorithm.
| Rule | Disease group | Amendment from previous version |
|---|---|---|
| 1 | Solid organ transplant recipients who remain on long term immune suppression therapy | Amendment improves specificity of selection by ensuring that there is evidence of condition and medication. |
| 2a |
Cancer undergoing active chemo/ radiotherapy or radical radiotherapy for lung cancer. |
No amendment to algorithm rules. The time window for the algorithm means a later set of data is used. |
| People having immunotherapy or other continuing antibody treatments for cancer * | No amendment | |
| People having other targeted cancer treatments which affect the immune system, such as protein kinase or PARP inhibitors. * | No amendment | |
| 2b | People with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma at any stage of treatment |
No amendment to algorithm rules. The time window for the algorithm means a later set of data is used. |
| People who have had bone marrow or stem cell transplants in the last 6 months, or still taking immunosuppression drugs. |
No amendment to algorithm rules. The time window for the algorithm means a later set of data is used. |
|
| 3 | People with severe respiratory conditions including all cystic fibrosis, severe asthma and severe COPD | Amendment improves specificity of selection by ensuring that there is evidence of condition and medication. |
| Cystic Fibrosis, idiopathic pulmonary Fibrosis, etc. Need to go straight through. Regardless of treatment. | Idiopathic pulmonary fibrosis and related interstitial fibrosis conditions were added to SNOMED-CT extract only. ICD coding was not added as it appears a number of bronchopneumonia have been coded into these categories. | |
| 4 | People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as SCID, homozygous sickle cell) | From analysis of this group during the production, unusual numbers of patients were found coded with D70 – Agranulocytosis, therefore this code was removed from this subset and account for this reduction. Note D70 is still within the cancer category and is captured in GP extracts. Minor numbers were lost due to clinical review of some genetic conditions, which do not carry increased infection risks. In addition, sickle cell disease was broken down in ICD10 into sub-categories to remove sickle cell trait. |
| People on immunosuppression therapies sufficient to significantly increase risk of infection | From analysis of this group during the production, unusual numbers of patients were found coded with D70 – Agranulocytosis, therefore this code was removed from this subset and account for this reduction. Note D70 is still within the cancer category and is captured in GP extracts. Minor numbers were lost due to clinical review of some genetic conditions, which do not carry increased infection risks. In addition, sickle cell disease was broken down in ICD10 into sub-categories to remove sickle cell trait. | |
| 5 | People who are pregnant with significant congenital heart disease | No amendment. |
Last edited: 6 October 2020 4:45 pm